Please login to the form below

Not currently logged in
Email:
Password:

Spark Therapeutics

This page shows the latest Spark Therapeutics news and features for those working in and with pharma, biotech and healthcare.

Roche to collaborate with Dyno on gene therapies for CNS/liver diseases

Roche to collaborate with Dyno on gene therapies for CNS/liver diseases

As part of the collaboration, Dyno will be responsible for the design of the novel AAV capsids, while Roche and its Spark Therapeutics division will develop the capsids in preclinical studies, ... This new partnership represents Dyno’s largest

Latest news

More from news
Approximately 17 fully matching, plus 35 partially matching documents found.

Latest Intelligence

  • After years of potential, cell and gene therapy is ready for the pharmaceutical mainstream After years of potential, cell and gene therapy is ready for the pharmaceutical mainstream

    Recent examples of this trend can be seen in Roche’s December 2019 $4.8bn takeover of Spark Therapeutics, one of the first US gene therapy firms to succeed in obtaining

  • Alzheimer’s: the search for a cure Alzheimer’s: the search for a cure

    Pharma’s return? Positive data on one of the combinations or approval of aducanumab could spark renewed interest in treating Alzheimer’s. ... Such a shift has recently happened in the gene therapy space, which was a backwater pursued largely by

  • Bluebird: on a mission to ‘recode’ the DNA of healthcare Bluebird: on a mission to ‘recode’ the DNA of healthcare

    Meanwhile, Spark Therapeutics’ Luxturna for a hereditary eye disease (marketed by Novartis in Europe) costs around $425, 000 per eye, bringing it close to that $1m mark. ... Fellow US gene therapy company Spark was acquired by Roche for $4.3bn in

  • Drug launches to watch in 2019 Drug launches to watch in 2019

    1. Zolgensma – the $4m per patient gene therapy. The first CAR-T cell therapies, Novartis’ Kymriah and Gilead/Kite’s Yescarta, were launched in Europe in 2018, while Spark’s gene ... Unlike fellow Boston, MA-based gene therapy company Spark

  • The European Medicines Agency: PRIME’d for access? The European Medicines Agency: PRIME’d for access?

    sales, and 6 are in the top 10 companies with Pfizer (with Spark Therapeutics), Novartis (by acquiring AveXis), Celgene (with Bluebird and through acquiring Juno Therapeutics), Sanofi, Roche and Merck all ... Those prices pale in comparison though when

More from intelligence
Approximately 0 fully matching, plus 11 partially matching documents found.

Latest appointments

  • Industry appointments Industry appointments

    Sigilon has already reached certain milestones for its Living Therapeutics product platform, including its Afibromer technology, which represents a new class of breakthrough implantable biomaterials. ... Vivaldi has more than 25 years’ experience and

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Apex.co.uk Events and Exhibition Stands

Apex.co.uk is one of the UK’s leading exhibition stand and event agencies, specialising in healthcare. We understand your communication goals,...

Latest intelligence

EU health fund
An EU emergency health fund to limit the impact of future crises
Leading finance experts propose an Emergency Health Financing Facility to limit the impact of future crises on the EU...
Mistrust in medical research: a patient perspective
The recent development of several COVID-19 vaccines has placed medical research firmly in the spotlight, highlighting public confusion and misinformation about clinical trials. Patient advocate, Trishna Bharadia reveals what the...
Real-world evidence: breaking boundaries in rare disease
Generating data for drug launches is a challenging process. In rare diseases, with small patient populations and high unmet need, evidence generation is even more complex. Consultant Sarah Poole and...

Infographics